Boyce Sarah
SEC-identified person · CIK 1629383 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Contineum Therapeutics, Inc. CTNM | Director | filed 2024 - 2026 |
| Atrium Therapeutics, Inc. RNA | Director | filed 2026 - 2026 |
| Avidity Biosciences, Inc. RNAM | Director · President and CEO | filed 2020 - 2026 |
| Omniab, Inc. OABI | Director | filed 2022 - 2024 |
| Ligand Pharmaceuticals INC LGNDD | Director | filed 2019 - 2022 |
| Phenomex Inc. CELL | Director | filed 2020 - 2021 |
| Akcea Therapeutics, INC. AKCA | Director · President | filed 2018 - 2019 |
| Isis Pharmaceuticals INC ISIS | Chief Business Officer | filed 2015 - 2018 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.